Clinical trials: HIV-1 Infection, open to volunteers
HIV-1 Infection, Acquired Immunodeficiency Syndrome
Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency
This pragmatic randomized controlled trial evaluates whether Fuyang Jiedu Granules combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure…
- Conditions
- HIV-1 Infection, Acquired Immunodeficiency Syndrome, Immune Reconstitution Failure, Immunological Non-responder
- Trial name
- FYJD-INR-pRCT (NCT07698548)
- Testing
- Fuyang Jiedu Granules, Antiretroviral Therapy (ART)
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Beijing University of Chinese Medicine
HIV -1 Infection
Study of GS-0415 and How It Works in People With HIV
The goals of this clinical study are to learn more about the study drug GS-0415, safety, tolerability, and pharmacokinetics (PK) of single ascending doses (SAD) and multiple ascending doses (MAD) of subcutaneous (SC) and…
- Trial name
- NCT07719491
- Testing
- GS-0415
- Where
- 16 sites in United States
- Volunteers
- 112 people
- Sponsor
- Gilead Sciences
HIV-1-infection
Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment
The study will have two portions: Phase 2 and Phase 3. Phase 2 will further have 2 parts: Part A and Part B. The goal of Phase 2, Part A is to assess the effectiveness of study drugs GS-3242 plus Lenacapavir (LEN) versus Biktarvy…
- Trial name
- NCT07708727
- Testing
- GS-3242 Tablet, GS-3242 Injection, Lenacapavir Tablet
- Where
- 16 sites in United States, Canada and 1 more
- Volunteers
- 700 people
- Sponsor
- Gilead Sciences
HIV Infection, HIV
#AWARE.HIV Europe: Supporting Healthcare Professionals to Find Undiagnosed HIV in European Hospitals: An Effectiveness-implementation Trial.
The #aware.hiv Europe study is a real-world, multicenter, stepped-wedge cluster randomized, effectiveness-implementation trial designed to evaluate whether the introduction of dedicated HIV teams in hospitals can improve HIV…
- Conditions
- HIV Infection, HIV, Stigma, Education
- Trial name
- #aware hiv (NCT06900829)
- Testing
- HIV team implementation
- Where
- 28 sites in Belgium, France and 8 more
- Volunteers
- 5,200 people, healthy volunteers welcome
- Sponsor
- Casper Rokx
HIV Infection, HIV
Baricitinib Curative Repression of HIV-1
This study is being done to test whether a drug called baricitinib, which blocks specific causes of inflammation, affects HIV-1 viral rebound and viral load levels after HIV treatment is discontinued.
- Trial name
- NCT07209267
- Testing
- Antiretroviral Therapy (ART), Baricitinib (LY3009104) 2 mg, Baricitinib (LY3009104) 4 mg
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Emory University
HIV -1 Infection
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV).
- Trial name
- NCT07392372
- Testing
- BNT351
- Where
- 6 sites in United States, Germany
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
HIV-1-infection
Ndovu RCT: Investing the Optimal Management of Dolutegravir Resistance
This clinical trial will address the gap in published data on the effect of dolutegravir (DTG)-associated drug-resistant mutations on viral suppression among people remaining on DTG-based antiretroviral therapy.
- Trial name
- NCT06747507
- Testing
- Dolutegravir Pill, Darunavir+Ritonavir
- Where
- 9 sites in Kenya, Lesotho and 2 more
- Volunteers
- 392 people
- Sponsor
- University of Nairobi
HIV Infection
Prevalence of Drug-resistant Hiv-1 Strains in Patients Experiencing Virologic Failure. (MULTIVIR2025)
In this cross-sectional, national and multicenter study, the main objective is to determine the prevalence of multi-drug resistant viruses (i.e., viruses that are resistant or possibly resistant to at least one antiretroviral…
- Trial name
- MULTIVIR2025 (NCT06842706)
- Volunteers
- 800 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV-1-infection, Multi-Antiviral Resistance
Italian Registry of HIV-1 Infected Patients With Drug-RESistant Virus to Reverse Transcriptase Inhibitors, InteGrasE and Viral Protease.
The PRESTIGIO Registry is an Observational, prospective, multicentre study that includes patients, regularly followed by Italian Infectious Disease Centres, with HIV-1 infection and documented resistance to the 4 classes of…
- Trial name
- PRESTIGIO (NCT04098315)
- Testing
- REGISTER CREATION
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Castagna Antonella